- Home
- IMMX vs SACH Comparison
IMMX vs SACH Comparison
Compare IMMX & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- SACH
- Stock Information
- Founded
- IMMX 2014
- SACH 2010
- Country
- IMMX United States
- SACH United States
- Employees
- IMMX N/A
- SACH N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- SACH Real Estate Investment Trusts
- Sector
- IMMX Health Care
- SACH Real Estate
- Exchange
- IMMX Nasdaq
- SACH Nasdaq
- Market Cap
- IMMX 50.1M
- SACH 47.8M
- IPO Year
- IMMX 2021
- SACH 2017
- Fundamental
- Price
- IMMX $2.09
- SACH $0.98
- Analyst Decision
- IMMX Strong Buy
- SACH Hold
- Analyst Count
- IMMX 1
- SACH 3
- Target Price
- IMMX $7.00
- SACH $2.25
- AVG Volume (30 Days)
- IMMX 59.6K
- SACH 206.1K
- Earning Date
- IMMX 05-20-2025
- SACH 05-01-2025
- Dividend Yield
- IMMX N/A
- SACH 18.43%
- EPS Growth
- IMMX N/A
- SACH N/A
- EPS
- IMMX N/A
- SACH N/A
- Revenue
- IMMX N/A
- SACH N/A
- Revenue This Year
- IMMX N/A
- SACH N/A
- Revenue Next Year
- IMMX N/A
- SACH N/A
- P/E Ratio
- IMMX N/A
- SACH N/A
- Revenue Growth
- IMMX N/A
- SACH N/A
- 52 Week Low
- IMMX $1.26
- SACH $0.96
- 52 Week High
- IMMX $2.71
- SACH $3.24
- Technical
- Relative Strength Index (RSI)
- IMMX 61.41
- SACH 40.88
- Support Level
- IMMX $1.92
- SACH $0.96
- Resistance Level
- IMMX $2.25
- SACH $1.05
- Average True Range (ATR)
- IMMX 0.17
- SACH 0.04
- MACD
- IMMX 0.03
- SACH -0.00
- Stochastic Oscillator
- IMMX 67.61
- SACH 14.50
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.